Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sotera Health Company (SHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sotera Health is a Nasdaq-listed provider of mission-critical sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses.
Investors can review Form 8-K filings that report material events such as quarterly financial results, secondary offerings of common stock by selling stockholders, amendments to credit agreements and settlements of specific legal matters. For example, recent 8-Ks describe secondary offerings in which affiliates of Warburg Pincus LLC and GTCR LLC sold shares of SHC, with the company noting that it did not receive proceeds from those sales. Other 8-Ks outline amendments to a first lien credit agreement and the terms of repriced term loans maturing in 2031.
Filings also discuss legal and regulatory developments, including a binding term sheet to resolve a defined group of ethylene oxide claims related to a former Sterigenics facility, and broader risk factors associated with EO and Co-60, regulatory compliance, international operations and leverage. These disclosures help readers understand the legal, operational and financial context around Sotera Health’s sterilization and lab testing activities.
On Stock Titan, users can track new SHC filings as they appear on EDGAR and use AI-powered summaries to interpret complex documents. This includes understanding the implications of current reports on Form 8-K, as well as locating annual and quarterly reports when they are filed, to see segment information for Sterigenics, Nordion and Nelson Labs, capital structure details and updated risk factor discussions.
Sotera Health Company is soliciting proxies for its 2026 virtual Annual Meeting on May 21, 2026, where stockholders will elect four Class III directors, vote on an advisory say-on-pay resolution, and ratify Ernst & Young LLP as auditor for 2026.
The proxy describes a classified, 11‑member board structure (after the meeting), lead independent director role, and extensive committee oversight of risk, compensation, and governance. It highlights 2025 results, including 20 consecutive years of revenue growth, revenue of $1.164 billion, net income of $77.9 million, and Adjusted EBITDA of $594 million with a 51.0% margin, and explains a pay‑for‑performance executive compensation program that adds three‑year performance share units and stock‑price‑linked incentives in response to investor feedback.
Sotera Health Co filed an initial insider ownership report for Erika Ostrowski, its SVP, General Counsel and Secretary. The filing shows she directly holds 57,538 shares of Common Stock, consisting of 32,180 Restricted Stock Units and 25,358 shares of Common Stock.
She also holds stock options over 20,419 and 11,740 underlying Common shares, each with a $14.59 exercise price, granted under the 2020 Omnibus Incentive Plan. In addition, she holds performance-based RSUs tied to 4,484 and 9,892 underlying shares, with exercise prices of $13.38 and $17.69, subject to vesting and performance conditions. The filing records her current holdings and does not show any new purchases or sales.
Sotera Health Co reported an insider equity event for former SVP, General Counsel and Secretary Alexander Dimitrief. On March 31, 2026, 7,941 shares of common stock were withheld at $14.34 per share to cover his tax obligations when 17,135 Restricted Stock Units granted on March 4, 2024 vested under the company’s 2020 Omnibus Incentive Plan upon his retirement. Following this tax-withholding disposition, he directly holds 312,040 shares of Sotera Health common stock.
Sotera Health Co filing: The Vanguard Group amended its Schedule 13G to report zero shares beneficially owned of Sotera Health common stock and 0% ownership of the class. The amendment follows an internal realignment where certain Vanguard subsidiaries now report holdings separately.
The filing states Vanguard has no sole or shared voting or dispositive power over Sotera Health shares and that no other single person holds more than 5% of the reported securities. The statement is signed by Vanguard's Head of Global Fund Administration.
Sotera Health Co filed an initial insider ownership report for Kenneth D. Krause, who is identified as a director of the company. This Form 3 filing does not list any transactions or current holdings, serving mainly to register his status as a reporting insider under SEC rules.
Sotera Health Company announced a board transition. Constantine S. Mihas plans to resign as a Class I director effective March 16, 2026, and the company states his resignation is not due to any disagreement over operations, policies, or practices.
Effective the same date, the Board appointed Kenneth D. Krause as a Class I director. Krause is Executive Vice President and Chief Financial Officer of Rollins, Inc., with prior senior finance and strategy roles at MSA Safety. He will serve on Sotera Health’s Audit Committee and Litigation Committee, is deemed independent under Nasdaq rules, will enter into a customary indemnification agreement, and will receive standard non-employee director cash and restricted stock unit compensation under the company’s policy.
Sotera Health Co disclosed that investment funds affiliated with Warburg Pincus sold 15,000,000 shares of Sotera Health common stock on March 6, 2026 in an underwritten public secondary offering at $15.27 per share. After this transaction, the Warburg Pincus entities continue to indirectly hold a total of 19,102,952 shares through Bull Holdco L.P. and Bull Co-Invest L.P.
Warburg Pincus–affiliated entities reported a major share sale in Sotera Health Co. On March 6, 2026, certain Warburg Pincus Entities sold 15,000,000 shares of Sotera Health common stock in an underwritten public secondary offering at $15.27 per share. After this transaction, Warburg Pincus–affiliated vehicles reported indirect holdings of 19,102,952 shares, consisting of 15,287,717 shares held by Bull Holdco L.P. and 3,815,235 shares held by Bull Co-Invest L.P. Each Warburg Pincus entity disclaims beneficial ownership beyond its pecuniary interest.
Sotera Health Co ownership update: a group of Warburg Pincus entities reports an aggregate position of 31,838,253 shares of Common Stock, representing approximately 11.2% of outstanding shares. The filing states the percentage is calculated using 284,392,079 shares outstanding as of February 17, 2026.
The Warburg Pincus Reporting Persons say they are party to a Stockholders Agreement with GTCR and other holders; the GTCR Sponsors are publicly reported to own 12,735,301 shares per a Form 4 filed March 10, 2026. Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership of shares held of record by the GTCR Sponsors except as set forth in the Stockholders Agreement.